Study on the progression-free phase of brigatinib/brigatinib in the treatment of ALK-positive non-small cell lung cancer

Brigatinib, also known as Brigatinib (Brigatinib), is a targeted drug with significant efficacy, specially designed to treat patients with non-small cell lung cancer (NSCLC) with ALK gene rearrangements. Although the drug has been shown in clinical trials to extend progression-free survival (PFS) in patients, actual results will vary among patients.

Progression-free survival is a key measure of the success of cancer treatment. It records the time between the start of treatment and the progression of the disease or death from any cause. The length of this indicator is affected by many factors, such as the patient's specific condition, overall health status, tumor development stage, genetic mutation status, past treatment history, as well as side effects during treatment and patient tolerance, etc.

In a study that included 222 patients whose disease continued to worsen despite having been previously treated with crizotinib, brigatinib demonstrated impressive efficacy. These patients were initially treated with 90 mg of brigatinib daily, with the dose increased to 180 mg after 7 days. The results showed that about 56% of patients had a complete or partial response to the drug, and this good response lasted for about 14 months.

Another study involving 275 patients who had not received ALK inhibitor therapy further confirmed the superiority of brigatinib. In this study, it took an average of 24 months for patients treated with brigatinib to experience worsening, compared with only 11 months for those treated with crizotinib.

However, it is worth noting that the therapeutic effect and patient tolerance of brigatinib may also be affected by multiple other factors, such as the patient's genetic mutation type and whether he has received other ALK inhibitor treatments. Therefore, when formulating treatment plans, doctors need to fully consider the patient's specific situation to achieve personalized and precise treatment.